Next >
Top 25 US Products by Sales: Lipitor clung on to the top spot but increasingly feels the impact of generic competition.
Top 20 Global Products: Biologics are increasing apace among the top product offerings, accounting for eight of the 20 biggest selling drugs.
Top 20 Global Therapeutic Classes: The surge in antidiabetics clearly reflects the consequences of lifestyle changes that are edging around the world.
Top 25 Corporations by US Sales: Pfizer holds on at home despite falling Lipitor sales, but the loss of the Lipitor patent at the end of 2011 will make this lead increasingly tenuous.
Top 25 Corporations by US Prescriptions: Increased prescribing of generics saw Watson, Amneal and Lupin Laboratories surge ahead in 2011.
Major patent expiries in 2012.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.